Anti-Globo-H antibodies in FFPE immunohistochemistry help identify therapy-eligible patients and monitor response across cancer types.
Immunohistochemistry of tumor biopsies detects low PD-L1 and substantial CLEVER-1 expression to identify patients likely to respond before treatment.